2018 Meeting of the. Working Group on Obesity, Diabetes and the High Risk Patient
|
|
|
- Peter Caldwell
- 5 years ago
- Views:
Transcription
1 ESH Organizer: Working Group on Obesity, Diabetes and the High Risk Patient EUROPEAN SOCIETY OF HYPERTENSION 2018 Meeting of the Working Group on Obesity, Diabetes and the High Risk Patient EUROPEAN SOCIETY OF HYPERTENSION April Chalkidiki, Greece Blue Lagoon Princess Hotel For further information please visit Site: Or send an to: obdiabwg@medcongress.gr MED CONGRESS Events Organizer Kalapothaki 3, GR Thessaloniki T: F: E: info@medcongress.gr
2 2018 Meeting of the Working Group on Obesity, Diabetes and the High Risk Patient SATURDAY APRIL REGISTRATIONS ROUND TABLE How to measure early vascular ageing from ABPM Antza X. (Thessaloniki, Greece) Aspirin in patients with cardiovascular risk. When? Grassos X. (Athens, Greece) Clinical trials update: blood pressure control in the Balkan countries Lovic D. (Nis, Serbia) LECTURES Chairman: Karagiannis A. (Thessaloniki, Greece) Statin associated diabetes mellitus Elisaf M. (Ioannina, Greece) Obstructive sleep apnea and hypertension Narkiewicz K. (Gransk, Poland) Boehringer sponsored Satellite Symposium Lecturer: Bakatselos S. (Greece) Servier sponsored Satellite Symposium Lecturer: Limperopoulos E., Doumas M. (Greece) SUNDAY APRIL ANTIHYPERTENSIVE TREATMENT Chairman: Nilsson P. (Malmo, Sweden) Refractory hypertension: diagnosis and treatment Redon J. (Valencia, Spain) Combination of drugs with multiple mechanisms of actions in cardiovascular research Grassi G. (Milan, Italy)
3 28-30 April Chalkidiki, Greece - Blue Lagoon Princess Hotel ROUND TABLE: TREATMENT OF DIABETES MELLITUS Chairman: Chatziagelaki E. (Athens, Greece) Optimal treatment of gestational diabetes mellitus Prof. Goulis D. (Thessaloniki, Greece) Pathophysiology of type 2 Diabetes in Obesity Finer N. (UK) Guidelines for the management of diabetes Nilsson P. (Malmo, Sweden) Which is the second drug after metformin in diabetes. DDP 4 or SGLT- 2? Papanas N. (Alexandroupolis, Greece) AZILSARTAN: WHY A NEW ANGIOTENSIN II ANTAGONIST IS USEFUL IN CLINICAL PRACTICE? Lecturer: Kotsis V. (Thessaloniki, Greece) Sponsorship by Vianex ROUND TABLE: HOW TO TREAT? Chairman: Van de Borne P. (Belgium) A patient with dyslipidemia and increased liver transaminases Athyros V. (Thessaloniki, Greece) Adolescent with white coat hypertension Stabouli S. (Thessaloniki, Greece) A patient with ischemic stroke and statin intolerance Tziomalos K. (Thessaloniki, Greece) Once or twice daily dosing with NOACs: Insights from a direct comparison between apixaban and rivaroxaban Kreutz R. (Germany) LUNCH BREAK ROUND TABLE: SMOKING, OBESITY Chairman: Savopoulos C. (Thessaloniki, Greece) Quit Smoking: Can improve CV disease? Kontakiotis T. (Thessaloniki, Greece) Guidelines for the management of obesity Toplak H. (Graz, Austria)
4 2018 Meeting of the Working Group on Obesity, Diabetes and the High Risk Patient ROUND TABLE: HOW TO TREAT? Chairman: Chatzitolios A. (Thessaloniki, Greece) A 75-year-old patient with heart failure and anemia Kaiafa G. (Thessaloniki, Greece) A 65-year-old patient with hypertension and increased arterial stiffness Van de Borne P. (Belgium) A 70 years old hypertensive during and after acute stroke Makaritsis K. (Larissa, Greece) MANAGEMENT OF HYPERTENSION IN DIABETES: WHAT DO META - ANALYSES SUGGEST? Chairman: Zebekakis P. (Thessaloniki, Greece) Lecturer: Zanchetti A. (Milan, Italy) PRACTICE GUIDELINES FOR THE TREATMENT OF HYPERTENSION, DIABETES AND DYSLIPIDEMIA IN OBESE PATIENTS Chairman: Nilsson P. (Malmo, Sweden) Lecturer: Kotsis V. (Thessaloniki, Greece) MONDAY APRIL LECTURES Chairmen: Athyros V. (Thessaloniki, Greece), Tsioufis K. (Athens, Greece) Hypertension and the brain Coca A. (Barcelona, Spain) Secondary hypertension Gkaliagkousi E. (Thessaloniki, Greece) LECTURES Chairman: Elisaf M. (Ioannina, Greece) Drug combinations in the treatment of hypertension Kotsis V. (Thessaloniki, Greece) How to treat: A 70-year-old patient with peripheral artery disease and hyperlipidemia, Michailidis D. (London, UK)
5 28-30 April Chalkidiki, Greece - Blue Lagoon Princess Hotel Astra-Ζeneca sponsored Satellite Symposium Chairman: Chatziagelaki E. (Athens, Greece) Lecturer: Kotsis V. (Thessaloniki, Greece) Industry sponsored Satellite Symposium LUNCH BREAK LECTURES Chairman: Goulis D. (Thessaloniki, Greece) Obesity and Diabetes Micic D. (Belgrade, Serbia) Treatment of diabetes in obesity Chatziagelaki E. (Athens, Greece) HOW WE TREAT A PATIENT, WITH HEART FAILURE WITH REDUCED EF AND RESERVED EF Lecturer: Papadopoulos C. (Thessaloniki, Greece) ANTICOAGULANT THERAPY IN HIGH RISK PATIENTS WITH ATRIAL FIBRILLATION Lecturer: Chatzis D. (Athens, Greece) Industry sponsored Satellite Symposium
6
Friday June 6, :00-11:30 Coffee Break
1 1 9:00-11:00 Round table: Internal Medicine Society of Northern Greece Facing the challenges of Hypertension treatment in high risk patients Chairpersons: Hatzitolios A. I., Savopoulos C. G. (Thessaloniki,
Coordinators of the Summer School. President of the Hellenic Atherosclerosis Society
SCIENTIFIC PROGRAM Thursday, June 29 t h, 2017 15.00 15.45 Registration desk open 15.45 16.00 Welcome address E. Liberopoulos K. Tziomalos Coordinators of the Summer School Welcome address C. Pitsavos
Saturday, 8 September 2018 Treatment options and update on statin treatment Chair: M. Kayikcioglu, V. Kotsis How far should we lower LDL?
Friday, 7 September 2018 11.00-11.45 Registrations 11.45-12.00 Introduction - Welcome Messages L. Tokgozoglu, V. Kotsis Atherosclerosis and cardiovascular risk update Chair: A. Tselepis, H. Kultursay 12.00-12.30
Editorial. Dear Colleagues,
Editorial Dear Colleagues, We are really very happy to welcome you again in Athens for joining us in the 5th Official pre-esh International Congress Satellite Symposium, entitled Update on Difficult to
Working Group on Blood Pressure and Heart Rate Variability European Society of Hypertension
Thursday, June 12 Monza (Mi) University of Milano-Bicocca Building U-8 Auditorium Milan (Italy) Working Group on Blood Pressure and Heart Rate Variability European Society of Hypertension Arterial baroreflex
Program Workshop The 7 th International Symposium on Cardiovascular Disease and Renal Dysfunction 2015
The 7 th International Symposium on Cardiovascular Disease and Renal Dysfunction 2015 Saturday January 17, 2015 Evgenidio Foundation, www.ypertash.gr Workshop How to protect your diabetic patient from
European Summer School
European Summer School Ønsker om deltagelse i nedenstående summerschool bedes fremsendt til undertegnede senest d.1/4 2008. Ansøgning på max 1 side, samt CV på max 1 side. Bestyrelsen vil herefter indstille
Program Workshop The 7 th International Symposium on Cardiovascular Disease and Renal Dysfunction 2015
The 7 th International Symposium on Cardiovascular Disease and Renal Dysfunction 2015 Saturday January 17, 2015 www.ypertash.gr Workshop How to protect your diabetic patient from cardiovascular and renal
Preliminary Programme
Preliminary Programme Advanced Search My Diary Print Back Friday, June 16 Saturday, June 17 Sunday, June 18 Monday, June 19 Hall Session Title Session Type 07:45 08:45 Red Hall 1 NEW MARKERS OF RENAL DAMAGE
PRELIMINARY PROGRAMME. 2nd European-Middle East Forum on Managing cardiovascular risk factors in clinical practice 6 December, Istanbul, Turkey
PRELIMINARY PROGRAMME 2nd European-Middle East Forum on Managing cardiovascular risk factors in clinical practice 6 December, 2013 - Istanbul, Turkey Background and aims of the conference Cardiovascular
Patient with high risk for bleeding
Will Apixaban change practice in atrial fibrillation Luncheon Satellite Sponsored by Pfizer Patient with high risk for bleeding Prof. Amos Katz M.D August 2012: patient background 67-year-old woman History
High Risk OSA n = 5,359
Table S1 Prevalence of atrial fibrillation (AF) identified using different methods in participants with high and low risk obstructive sleep apnea (). High Risk n = 5,359 Low Risk n = 14,992 SR-AF (%) 467
Pan American Heart Failure Congress (PAHF 2012) October 18 th -21 th 2012 Panama City, Panama
Pan American Heart Failure Congress (PAHF 2012) October 18 th -21 th 2012 Panama City, Panama Congress Chairman Uri Elkayam, MD Professor of Medicine University of Southern California, Keck School of Medicine
Long-Term Care Updates
Long-Term Care Updates October/November 2015 By Daniel Kerner, PharmD A stroke occurs when blood flow to the brain is stopped or slowed, resulting in death or damage to brain cells. There are three main
Atrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
Disclosures. May 15 th, Influenza Vaccination as Secondary Prevention for Acute Coronary Events Where do we need to go in clinical practice?
Influenza Vaccination as Secondary Prevention for Acute Coronary Events Where do we need to go in clinical practice? May 15 th, 2014 Robi Goswami, MD Cardiologist Piedmont Heart Institute Disclosures None
5 th Annual Meeting Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group November 15-17, 2012 Paris, France
5 th Annual Meeting Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group November 15-17, 2012 Paris, France Thursday, November 15, 2012 18:00 19:30 DPP- 4 and cardiovascular disease Chairs: Ceriello
Q1 In which country and city is your centre based?
Q1 In which country and city is your centre based? Answered: 41 Skipped: 0 # Date 1 Poland, Warsaw 7/2/2017 11:55 PM 2 Poland, Polanica Zdrój 7/2/2017 10:08 PM 3 Poland 6/30/2017 11:34 PM 4 italy 6/30/2017
White coat and masked hypertension
White coat and masked hypertension Conflict of interest Support from Spacelabs, Microlife. Honoraria from Novartis, Elpen, Boeringer-Ingelheim, CANA, Lilly, MSD, Sanofi, Menarini, Ciezi, Astra-Zeneca.
WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017
WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017 Mary L. Yost 404-520-6652 , LLC 23 Ridge Rd. Beaufort, SC 20097 Copyright Pending 2017 All rights reserved,
Supplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
Scientific Committee. Organizing Committee G. Athanassopoulos G. Karatasakis S. Kyrzopoulos D. Tsiapras GENERAL INFORMATION
Organizing Committee G. Athanassopoulos G. Karatasakis S. Kyrzopoulos D. Tsiapras Scientific Committee G. Athanassopoulos G. Karatasakis S. Kyrzopoulos D. Tsiapras G. Kolovou A. Chaidaroglou S. Fragoulis
Nordic-Baltic Region University Research Course Gdańsk, Poland, September 19-21, 2019
Nordic-Baltic Region University Research Course Gdańsk, Poland, September 19-21, 2019 HYPERTENSION AND CARDIOVASCULAR DISEASE: Focus on Brain, Cognition, Stroke and Sympathetic Nervous System Activity
Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study
Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Dr. Antonio Magaña M.D. (on behalf I-PREFER investigators group) Stockholm, Sweden, August
Welcome address - Invitation
Welcome address - Invitation The 1st Department of Obstetrics and Gynaecology of the Aristotle University Medical School, Thessaloniki, Greece, in collaboration with Biogenesis & Research Instruments Ltd
Atrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
BARCELONA HALL 8 - GRAN VIA BARCELONA
th EUROPEAN MEETING ON AND CARDIOVASCULAR PROTECTION WWW.ESH2018.EU JUNE 8-11, 2018, FIRA BARCELONA HALL 8 - GRAN VIA BARCELONA SPONSOR TIMETABLE OPPORTUNITIES FRIDAY, JUNE 8 M1 M2 13.30 14.30 14.30 16.00
An international, double-blind, phase III randomized trial. Main Results
An international, double-blind, phase III randomized trial Main Results Robert Hart on behalf of the NAVIGATE ESUS Steering Committee and Investigators Sponsorship & Disclosures NAVIGATE ESUS was sponsored
Index. Note: Page numbers of article titles are in boldface type.
Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced
XXI Congress of the Cardiology Society of Serbia (CSS) Preliminary Programme Zlatibor, October, 2017
XXI Congress of the Cardiology Society of Serbia () Preliminary Programme Zlatibor, 19-22 October, 15.00 Interventional Cardiology in Serbia 15.15 15.30 15.45 16.00 16.15 at the Congress Thursday, October
After acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
ANGIOTENSIN RECEPTOR BLOCKERS ARE FIRST LINE TREATMENT : PRO
ANGIOTENSIN RECEPTOR BLOCKERS ARE FIRST LINE TREATMENT : PRO Prof Xavier Girerd M.D., Ph.D., F.E.S.C. Endocrinology Department Cardiovascular Prevention Unit Groupe Hospitalier Pitié-Salpêtrière Faculté
A Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION
Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Dr Kornelia Kotseva National Heart & Lung Insitute Imperial College London, UK on behalf of all investigators participating
THE CVD CHALLENGE IN NORTHERN IRELAND. Together we can save lives and reduce NHS pressures
THE CVD CHALLENGE IN NORTHERN IRELAND Together we can save lives and reduce NHS pressures The challenge of CVD continues today. Around 225,000 people in Northern Ireland live with the burden of cardiovascular
Declaration of conflict of interest
Declaration of conflict of interest Prevalence and main features of resistant hypertension in Central and Eastern Europe: data from the G. Brambilla 1, G. Seravalle 2, R. Cifkova 3, C. Farsang 4, S. Laurent
Apixaban versus Heparin/Vitamin K Antagonist in Anticoagulation-naïve Patients with Atrial Fibrillation Scheduled for Cardioversion: The EMANATE Trial
Apixaban versus Heparin/Vitamin K Antagonist in Anticoagulation-naïve Patients with Atrial Fibrillation Scheduled for Cardioversion: The EMANATE Trial Michael D. Ezekowitz, Professor, Sidney Kimmel Medical
EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial
EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial RP Giugliano, F Mach, K Zavitz, AC Keech, TR Pedersen, MS Sabatine, P Sever, C Kurtz, N Honarpour, BR Ott, on behalf of the EBBINGHAUS
oncology For 9 th eso-esmo course on July 2012 ioannina, Greece
ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA ioannina 21/07/12 9 th eso-esmo course on oncology For medical students 21-27 July 2012 ioannina, Greece chair: N. Pavlidis, GR core faculty: R.A. Audisio, UK
PRELIMINARY PROGRAM. 11 th International Workshop on Peritoneal Surface Malignancy SEPTEMBER 9-11,
11 th International Workshop on Peritoneal Surface Malignancy PRELIMINARY PROGRAM SEPTEMBER 9-11, 2018 Maison de la Chimie, Paris, France www.psogi2018.com 9THSATURDAY 8TH 2SUNDAY Saturday, September 8
To provide clinically relevant information about Clinical Nutrition.
16. th ESPEN Course in Clinical Nutrition Fruska Gora, Norcev Serbia, October 8 th 14 th, 2009. Aims To provide clinically relevant information about Clinical Nutrition. To enable participants to start
AOPT. 13 Scientific Meeting OCULAR THERAPEUTICS: VISION OF HOPE IN A CHANGING WORLD. February 16th-19th, Florence (Italy)
AOPT th 13 Scientific Meeting Association for Ocular Pharmacology and Therapeutics February 16th-19th, 2017 Florence (Italy) OCULAR THERAPEUTICS: VISION OF HOPE IN A CHANGING WORLD www.aopt.org ATTENDEES
The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension
The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension Michael Böhm, MD on behalf of the GSR Investigators March 30,
Strategies to Reduce Premature Cardiovascular Morbidity and Mortality
Premature Cardiovascular Cartagena de Indias, COLOMBIA, 2018 Congress Venue: Hotel Estelar Cartagena de Indias Organized by: LASH Sociedad Latino Americana de Hipertension Arterial SCCH Sociedad Centroamericana
Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure
Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure CI Liakos, 1 EA Sanidas, 1 DN Perrea, 1 V Gennimata, 1 V Chantziara, 1 CA Grassos, 2 N-A Viniou, 1 JD Barbetseas,
Professional International Study Management
Professional International Study Management Services Phase I Study Consulting Phase II-IV IV Study Conduct for Drugs and Devices Protocol Design and Development Study Feasibilities Site Identification,
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy. Ziad Hijazi, MD
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy Ziad Hijazi, MD Uppsala Clinical Research Center (UCR) Uppsala University, Sweden Co-authors:
Aldo P. Maggioni, Kees Van Gool, Nelly Biondi, Renato Urso, Niek Klazinga, Roberto Ferrari, Nikolaos Maniadakis and Luigi Tavazzi.
Appropriateness of prescriptions of recommended treatments in OECD health systems: findings based on the Long-Term Registry of the ESC on Heart Failure Aldo P. Maggioni, Kees Van Gool, Nelly Biondi, Renato
Eliquis and plavix combination therapy
Eliquis and plavix combination therapy ELIQUIS Dosing for Patients With NVAF. patients treated with aspirin or the combination of bleeding or completion of a course of therapy,. 9-11-2011 Thrombosis is
Evaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
Editorial. Dear Colleagues,
Dear Colleagues, Editorial We are really very happy to welcome you again in Athens for joining us in the 6th Official pre-esh International Congress Satellite Symposium, entitled Update on Difficult to
GLORIA -AF REGISTRY PROGRAMME
GLORIA -AF REGISTRY PROGRAMME EXECUTIVE SUMMARY The approval of novel oral anticoagulants has changed prescribing patterns for stroke prevention in atrial fibrillation (AF) worldwide. 1 There is a need
Core Curriculum for the Cardiovascular Clinician
September 14 17, 2016 Heart House Washington, DC AGENDA Wednesday, September 14 PHARMACOLOGY WORKSHOP 5:30 p.m. Registration and Light Refreshments 6:00 p.m. Welcome and Introductions 6:15 p.m. CVD Guideline-driven
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
Disclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
Editorial. Dear Colleagues,
Editorial Dear Colleagues, We are really very happy to welcome you again in Athens for joining us in the 6th Off icial pre-esh International Congress Satellite Symposium, entitled Update on Diff icult
October 25-26, 2018 Infinity Hotel & Conference Resort, Munich, Germany
Programme 4 th CVOT Summit in cooperation with D&CVD EASD Study Group October 25-26, 2018 Infinity Hotel & Conference Resort, Munich, Germany Thursday, October 25, 2018 Room Ammersee I 18:00 18:30 Welcome,
DECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None Dietary changes and its influence on cardiovascular diseases in Asian and European countries Problems of Eastern European countries for cardiovascular disease prevention
Consensus document: Screening and Prevention of Atrial Fibrillation
Consensus document: Screening and Prevention of Atrial Fibrillation Yong-Seog Oh, M.D.,Ph.D. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary s Hospital, College of Medicine, The
The most accurate predictors of arterial hypertension in patients with Obstructive Sleep Apnea Syndrome
The most accurate predictors of arterial hypertension in patients with Obstructive Sleep Apnea Syndrome Natsios Georgios University Hospital of Larissa, Greece Definitions Obstructive Sleep Apnea (OSA)
THURSDAY, 30 JUNE, 2016 FRIDAY, 1 JULY 2016
THURSDAY, 30 JUNE, 2016 18:00 18:30 OPENING CEREMONY Opening Lecture: TBA 18:30 19:30 Chairs: Maciej Banach (); Nathan D. Wong (Irvine, USA) 19:30 Get Together Reception FRIDAY, 1 JULY 2016 08:30 - Plenary
PRELIMINARY PROGRAMME
PRELIMINARY PROGRAMME 26 May 2017 ITALIAN LANGUAGE SYMPOSIUM PHARMACOLOGY IN INTERVENTIONAL CARDIOLOGY DAPT AFTER PCI 10.00 CONTROVERSY 1 - P2Y12 INHIBITION AFTER PCI IN STABLE PATIENTS Clopidogrel remains
4:30 p.m. Jack Vogel Memorial Lecture Evolution and Revolution in the Treatment of Valvular Heart Disease Dr. Mack
AGENDA Friday, January 12 4:30 p.m. Registration at Westin Snowmass Conference Center 6:30 p.m. Saturday, January 13 3:30 p.m. Registration and Refreshment Break SESSION I Moderator: 4:00 p.m. Welcome
KIDNEY LIVER MEETS FINAL PROGRAM KIDNEY MEETS LIVER. When the excellence in renal and liver medicine come together. XXXXXXX
XXXXXXX When the excellence in renal and liver medicine come together. 1 COMITATI SCIENTIFIC PROGRAM Organizing Committee Prof. Michel Jadoul Chief Service de Nephrologie Clinique Universitaire Saint-Luc
Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
European Academy of Paediatrics 2017 Congress and MasterCourse (EAP 2017) Preliminary Programme * As of August 18, Thursday, October 12, 2017
Thursday, October 12, 2017 EAP 2017 MasterCourse Infectious Diseases 08:30-08:45 MasterCourse Welcome & Organizational Introduction Hall A 08:45-11:00 Group 1 11:00-11:30 Coffee Break Group 2 Group 3 MasterCourse
DFSG September 2018 Germany
Sponsor & Exhibitor Information DFSG 2018 28 30 September 2018 Germany 15 th Scientific Meeting of the Diabetic Foot Study Group Advancement of knowledge on all aspects of diabetic foot care www.dfsg.org
REGISTER TODAY! February 9, Sheraton Mahwah Hotel. Program Directors 2 ND ANNUAL COMPREHENSIVE CV DISEASE MANAGEMENT:
2 ND ANNUAL COMPREHENSIVE CV DISEASE MANAGEMENT: FROM FUNDAMENTALS TO INNOVATION 2018 February 9, 2018 7 am - 5 pm CME Symposium Sheraton Mahwah Hotel 1 International Blvd. (Rte. 17 North) Mahwah, NJ 07495
Prof. Renata Cífková, MD, CSc.
Prof. Renata Cífková, MD, CSc. Head of the Department of Preventive Cardiology, Thomayer Teaching Hospital, Prague Focuses on arterial hypertension epidemiology, clinical trials, target organ damage prevention
Hypertension and Stroke: new data
Hypertension and Stroke: new data Antonio Coca, MD, PhD, FRCP Hypertension Unit. Institute of Internal Medicine and Dermatology. Hospital Clínic (IDIBAPS). University of Barcelona, Spain WG Seminars. Hellenic
Advances in Internal Medicine May 2017 Post-Test
Advances in Internal Medicine May 2017 Post-Test 1 Which of the following requires the SHORTEST duration of dual anti-platelet therapy, according to 2016 ACC/AHA guidelines? A. Bare metal stent for stable
International Symposium on: URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE
International Symposium on: URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE Bologna (Italy), November 13 th 14 th, 2018 Organized by UNITÀ OPERATIVA MEDICINA INTERNA AZIENDA OSPEDALIERO UNIVERSITARIA
Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke
«L Europe de la santé au service des patients» 13-14 October 2008 - Institut Pasteur Paris Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke Simona Giampaoli National Centre of
PCHF. A novel course in heart failure management POSTGRADUATE COURSE IN HEART FAILURE
PCHF POSTGRADUATE COURSE IN HEART FAILURE A novel course in heart failure management Certified by the European Society of Cardiology (ESC) and the University of Zurich. Based on the new curriculum of the
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
8-10 September 2017 Porto, Portugal
Sponsor & Exhibitor Information 8-10 September 2017 Porto, Portugal 14th Scientific Meeting of the Diabetic Foot Study Group Advancement of knowledge on all aspects of diabetic foot care Porto, Portugal
HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
PULMONARY HYPERTENSION. by CLINICAL CASES. An educational event of the University of Bologna Master Degree in Pulmonary Vascular Diseases
Under the Aegis of PULMONARY HYPERTENSION by CLINICAL CASES An educational event of the University of Bologna Master Degree in Pulmonary Vascular Diseases BOLOGNA June 28-29, 2013 Palazzo dell Archiginnasio
Safety Pharmacology Post Meeting Survey 2014
Q1 Please enter your personal information below. (If you want to be included in the 2014 Annual Meeting survey for a chance to win $200, this information is REQUIRED) Answered: 132 Skipped: 14 Name: Company:
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
ischemic stroke, transient ischemic attack, or peripheral artery embolism
Appendix Table S1: ICD- 8/1 codes and ATC- codes Population Acute myocardial infarction Defined from primary inpatient diagnoses codes PCI Defined from procedure codes Non- valvular atrial fibrillation
FROM RISK FACTORS TO TARGET ORGAN DAMAGE: HOW TO DIAGNOSE HOW TO TREAT Highlights
Introduction FROM RISK FACTORS TO TARGET ORGAN DAMAGE: HOW TO DIAGNOSE HOW TO TREAT Highlights Thessaloniki (Greece), March 10-11, 2017 Prof. Manolis, chairman of the symposium, opened the congress, by
Preliminary Programme Hotel du Lac, Ioannina, Greece (Congress Halls, Main Building) Educational Edition Greece 2014
Organized by: International Symposium Intra Articular Treatment National Foundation of Ultrasound Guided Hip Intra-Articular Therapy (ANTIAGE) www.antiagefbf.it In collaboration with: Rheumatology Clinic,
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Warfarin and the risk of major bleeding events in patients with atrial fibrillation: a population-based study Laurent Azoulay PhD 1,2, Sophie Dell Aniello MSc 1, Teresa
Defining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
Show Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
8 th International Workshop on Interventional Pediatric Cardiology Milan, March 31 st - April 2 nd 2011
8 th International Workshop on Interventional Pediatric Cardiology Milan, March 31 st - April 2 nd 2011 MARCH 31 st 2011 7.15-7.50 REGISTRATION 7.50-8.00 WELCOME AND INTRODUCTION M. Carminati (Italy) 8.00-10.00
ESSKA Advanced Shoulder Arthroscopy Course. ALL About Instability & OTHER Glenohumeral Disorders June 2017 in Verona, Italy
ESSKA Advanced Shoulder Arthroscopy Course ALL About Instability & OTHER Glenohumeral Disorders 12-13 June 2017 in Verona, Italy The ESSKA Advanced Shoulder Arthroscopy Course is designed to provide certified
Condition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9
Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants (OACs) and warfarin in daily clinical practice: A propensity weighted nationwide cohort study. Supplementary material
EAS Congress Innsbruck Highlights: A programme to excite, inspire and inform!
Press release 84 th European Atherosclerosis Society Congress, Innsbruck, Austria For circulation 29 th May, 2016. 84 th Annual Congress of the European Atherosclerosis Society (EAS) May 29 th - June 1
Variables in Riksstroke - TIA
Variables in Riksstroke - TIA The TIA registration started 2010 for patients treated in hospital and 2015 it was 67 of 72 hospitals are registrating TIA On the www.riksstroke.org/forms/ you find the Riksstroke
hypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
On behalf of the RE-CIRCUIT Investigators. March 19, :45 am 10:55 am. Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Safety and Efficacy of Uninterrupted Anticoagulation with Dabigatran Etexilate versus in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study Hugh Calkins, M.D., 1 Stephan
ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE
ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE HELEN WILLIAMS FFRPS, MRPHARMS, PGDIP (CARDIOL) IPRESC CONSULTANT PHARMACIST FOR CVD, SOUTH LONDON CLINICAL LEAD FOR ATRIAL FIBRILLATION, HEALTH INNOVATION
American College of Cardiology 66th Annual Scientific Session (ACC.17):
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com American College of Cardiology 66th Annual Scientific
Version 1.11 of 20/07/2018
Version 1.11 of 20/07/2018 NICE JANUARY 17-19, 2019 6 th International Workshop on Lung Health New approaches to respiratory diseases PRESIDENTS: F. BLASI, G.W. CANONICA CHAIRMEN: S. CENTANNI, J.C. VIRCHOW,